WO2006089141A3 - Antibodies against cxcr4 and methods of use thereof - Google Patents

Antibodies against cxcr4 and methods of use thereof Download PDF

Info

Publication number
WO2006089141A3
WO2006089141A3 PCT/US2006/005691 US2006005691W WO2006089141A3 WO 2006089141 A3 WO2006089141 A3 WO 2006089141A3 US 2006005691 W US2006005691 W US 2006005691W WO 2006089141 A3 WO2006089141 A3 WO 2006089141A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
cxcr4
methods
medicament
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/005691
Other languages
French (fr)
Other versions
WO2006089141A2 (en
Inventor
Wayne A Marasco
Jianhua Sui
Chen Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Priority to EP06748215A priority Critical patent/EP1871807B1/en
Priority to US11/883,258 priority patent/US8329178B2/en
Priority to CA2597717A priority patent/CA2597717C/en
Publication of WO2006089141A2 publication Critical patent/WO2006089141A2/en
Publication of WO2006089141A3 publication Critical patent/WO2006089141A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides human monoclonal antibodies, scFv antibodies, scFv-Fc fusions, a dAb (domain antibodies), Fab, Fab' and F(ab')2 fragments, single chain antibodies and/or minibodies that specifically bind to CXCR4. Also provided are methods of treating and/or preventing a CXCR4 disease or disorder such as cancer and X4-tropic HIV-I infection as well as uses of such antibodies and antibody fragments in the manufacture of a medicament for the treatment or prevention of a CXCR4 disorder. The invention also provides methods of preventing diseases or disorders associated with CXCR4 function or expression. The invention further provides for the use of the antibodies (or fragments thereof) of the invention in the manufacture of a medicament for the prevention of diseases or disorders associated with CXCR4 expression. Also provided are methods of treating or preventing cancer metastasis in a patient suffering from a cancer involving tumor cells that express CXCR4. The invention also encompasses the use of such antibodies and antibody fragments in the manufacture of a medicament for the treatment or prevention of cancer metastasis. The invention also includes methods of treating or preventing cancer metastasis in a patient suffering from a hypoxic tumor, such as any solid tumor characterized by HIF- dependent CXCR4 activation. The antibodies and fragments disclosed herein can be used in the manufacture of a medicament for the prevention of cancer metastasis in a patient suffering from a hypoxic tumor. The invention additionally provides methods of mobilizing CD34+ stem cells from the bone marrow as wells methods of blocking chemotaxis of CXCR4-expressing cells in response to SDF-1. Also provided are methods of treating or preventing graft-versus-host disease as well as the use of the antibodies and fragments thereof in the manufacture of a medicament for the prevention or treatment of GVHD. Finally, the invention also provides methods of inhibiting the formation of new tumor blood vessels and/or inhibiting tumor cell angiogenesis.
PCT/US2006/005691 2005-02-18 2006-02-15 Antibodies against cxcr4 and methods of use thereof Ceased WO2006089141A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP06748215A EP1871807B1 (en) 2005-02-18 2006-02-15 Antibodies against cxcr4 and methods of use thereof
US11/883,258 US8329178B2 (en) 2005-02-18 2006-02-15 Antibodies against CXCR4 and methods of use thereof
CA2597717A CA2597717C (en) 2005-02-18 2006-02-15 Antibodies against cxcr4 and methods of use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65437705P 2005-02-18 2005-02-18
US60/654,377 2005-02-18

Publications (2)

Publication Number Publication Date
WO2006089141A2 WO2006089141A2 (en) 2006-08-24
WO2006089141A3 true WO2006089141A3 (en) 2006-12-07

Family

ID=36917101

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/005691 Ceased WO2006089141A2 (en) 2005-02-18 2006-02-15 Antibodies against cxcr4 and methods of use thereof

Country Status (4)

Country Link
US (1) US8329178B2 (en)
EP (1) EP1871807B1 (en)
CA (1) CA2597717C (en)
WO (1) WO2006089141A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof
EP2018436A2 (en) * 2006-04-25 2009-01-28 Immune Disease Institute Inc. Targeted delivery to leukocytes using non-protein carriers
MX2009003306A (en) * 2006-10-02 2009-04-23 Medarex Inc Human antibodies that bind cxcr4 and uses thereof.
US9512236B2 (en) 2006-12-19 2016-12-06 Ablynx N.V. Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
FR2915102B1 (en) * 2007-04-23 2014-05-16 Pf Medicament USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER
RU2010127156A (en) 2007-12-06 2012-01-20 Дана-Фарбер Кэнсер Инститьют, Инк. (Us) ANTIBODIES AGAINST INFLUENZA VIRUS AND THEIR APPLICATION
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
CN102027015A (en) * 2008-05-14 2011-04-20 伊莱利利公司 Anti-CXCR4 antibodies
EP2285833B1 (en) 2008-05-16 2014-12-17 Ablynx N.V. AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
WO2012019168A2 (en) * 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN103917560B (en) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 Bispecific anti-CXCR7 immunoglobulin single variable domains
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
AR087363A1 (en) * 2011-07-29 2014-03-19 Pf Medicament USE OF ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCERES
CN104039320B (en) 2011-11-09 2019-10-15 百时美施贵宝公司 Treatment of hematological malignancies with anti-CXCR4 antibodies
WO2014107165A1 (en) * 2013-01-05 2014-07-10 R-PHARM, CJSC (Closed Joint Stock Company) Fully human antibodies against human receptor igf-1r
CA2919790C (en) * 2013-08-02 2018-06-19 Pfizer Inc. Anti-cxcr4 antibodies and antibody-drug conjugates
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
EP3233112A2 (en) * 2014-12-17 2017-10-25 Cancer Research Technology Limited Anti-cxcl12 antibody molecules and their uses
EP3233900A2 (en) 2014-12-19 2017-10-25 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptors and methods of use thereof
US11890348B2 (en) * 2015-09-18 2024-02-06 The General Hospital Corporation Localized delivery of anti-fugetactic agent for treatment of cancer
RU2769282C2 (en) 2016-06-20 2022-03-30 Кимаб Лимитед Anti-pd-l1 and il-2 cytokines
WO2018069871A2 (en) 2016-10-13 2018-04-19 Sorrento Therapeutics, Inc. Anti-kras binding proteins
CN120795163A (en) 2016-10-14 2025-10-17 丹娜法伯癌症研究所公司 Modular tetramer bispecific antibody platform
US12384830B2 (en) 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
AU2019235900B2 (en) * 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same
CA3119644A1 (en) 2018-11-30 2020-06-04 Dana-Farber Cancer Institute, Inc. Chimeric antigen receptor factories and methods of use thereof
JP7489407B2 (en) 2019-05-21 2024-05-23 ノバルティス アーゲー CD19 binding molecules and uses thereof
WO2021011480A1 (en) * 2019-07-12 2021-01-21 The Research Foundation For The State University Of New York Compositions and methods to block and bind cxcr4 to modulate cellular function
JP2023509760A (en) 2020-01-08 2023-03-09 シンシス セラピューティクス，インコーポレイテッド ALK5 inhibitor complexes and uses thereof
CA3245541A1 (en) 2022-03-09 2023-09-14 Dana-Farber Cancer Institute, Inc. Genetically engineered b cells and methods of use thereof
CN117003876B (en) * 2023-08-31 2024-06-18 恺佧生物科技(上海)有限公司 Anti-CXCR4 membrane protein antibody and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042074A1 (en) * 1999-01-15 2000-07-20 Millennium Pharmaceuticals, Inc. Anti-ccr4 antibodies and methods of use therefor
WO2001042308A2 (en) * 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
WO2003066830A2 (en) * 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
WO2004059285A2 (en) * 2002-12-23 2004-07-15 Protein Design Labs, Inc. Tumor killing/tumor regression using cxcr4 antagonists
EP1449850A1 (en) * 2001-08-31 2004-08-25 Kyowa Hakko Kogyo Co., Ltd. Human cdr-grafted antibodies and antibody fragments thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (en) 1989-06-29 1997-03-16 Medarex Inc BI-SPECIFIC REAGENTS FOR AIDS THERAPY.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE158021T1 (en) 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
ES2301158T3 (en) 1992-07-24 2008-06-16 Amgen Fremont Inc. XENOGENIC ANTIBODY PRODUCTION.
DK0752248T3 (en) 1992-11-13 2000-11-13 Idec Pharma Corp Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antibody
EP0745134A1 (en) 1994-02-22 1996-12-04 Danafarber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
EP1246607B1 (en) 1999-12-30 2007-06-27 Dana-Farber Cancer Institute, Inc. Proteoliposomes containing an integral membrane protein having one or more transmembrane domains
US7138496B2 (en) * 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
WO2006089141A2 (en) 2005-02-18 2006-08-24 Dana-Farber Cancer Institute Antibodies against cxcr4 and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042074A1 (en) * 1999-01-15 2000-07-20 Millennium Pharmaceuticals, Inc. Anti-ccr4 antibodies and methods of use therefor
WO2001042308A2 (en) * 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
EP1449850A1 (en) * 2001-08-31 2004-08-25 Kyowa Hakko Kogyo Co., Ltd. Human cdr-grafted antibodies and antibody fragments thereof
WO2003066830A2 (en) * 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
WO2004059285A2 (en) * 2002-12-23 2004-07-15 Protein Design Labs, Inc. Tumor killing/tumor regression using cxcr4 antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAPTEVA NATALIA ET AL: "CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo.", CANCER GENE THERAPY. JAN 2005, vol. 12, no. 1, January 2005 (2005-01-01), pages 84 - 89, XP002397865, ISSN: 0929-1903 *
OTTAIANO ALESSANDRO ET AL: "Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 54, no. 8, 11 December 2004 (2004-12-11), pages 781 - 791, XP002397864, ISSN: 0340-7004 *
VADAY GAYLE G ET AL: "CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 15 AUG 2004, vol. 10, no. 16, 15 August 2004 (2004-08-15), pages 5630 - 5639, XP002397863, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
CA2597717C (en) 2014-10-21
US8329178B2 (en) 2012-12-11
EP1871807A2 (en) 2008-01-02
EP1871807B1 (en) 2012-11-28
WO2006089141A2 (en) 2006-08-24
CA2597717A1 (en) 2006-08-24
US20110250165A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
WO2006089141A3 (en) Antibodies against cxcr4 and methods of use thereof
RU2421464C2 (en) Human il-13 antibodies and their therapeutic application
WO2005054273A3 (en) Humanized antibodies against vascular endothelial growth factor
JOP20220352A1 (en) CCR8 antibody therapy: Biomarkers and combination therapies
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
WO2007075270A3 (en) Multivalent immunoglobulin-based bioactive assemblies
AU2018263862A1 (en) Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof
WO2004032857A3 (en) Antibody therapy
WO2005102387A3 (en) Therapeutic use of anti-cs1 antibodies
PL377337A1 (en) Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
JP2020536109A5 (en)
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
WO2007115049A3 (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2008156713A3 (en) Anti-cd20 therapeutic compositions and methods
WO2006062779A3 (en) Anti-integrin immunoconjugates, methods and uses
MXPA05012011A (en) Therapeutic use of anti-cs1 antibodies.
MX2010005099A (en) Uses of anti-cd40 antibodies.
WO2005061544A3 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
ZA202302392B (en) Antibodies against ilt2 and use thereof
MX2021002605A (en) Anti-cxcl13 antibodies for treating autoimmune diseases and cancer.
MX2025006057A (en) Anti-cea antibody drug conjugates and methods of use
WO2009015908A3 (en) Anti ephb4 antibodies and antibody fragments
MX2025001452A (en) Anti-ccr8 antibodies and methods of use
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2597717

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11885125

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006748215

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application